Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) shot up 2.4% during trading on Friday . The company traded as high as GBX 642 and last traded at GBX 642. 8,467 shares were traded during mid-day trading, a decline of 61% from the average session volume of 21,607 shares. The stock had previously closed at GBX 627.
Hemogenyx Pharmaceuticals Trading Up 2.4%
The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The business’s 50-day moving average is GBX 652.50 and its two-hundred day moving average is GBX 641.39. The firm has a market cap of £38.78 million, a P/E ratio of -2.78 and a beta of 3.14.
Hemogenyx Pharmaceuticals Company Profile
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Articles
- Five stocks we like better than Hemogenyx Pharmaceuticals
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
